Saladax Biomedical has received CE mark for its MyPaclitaxel and MyDocetaxel therapeutic dose management (TDM) MyCare assays, enabling commercialisation in the European Union (EU). Both paclitaxel and docetaxel are administered based on a ...
Tags: Saladax Biomedical, Saladax's MyCare technology platform, MyCare tests
Saladax Biomedical has signed a distribution contract with INyDIA Labs for My5-FU, a test that measures levels of 5-fluorouracil (5-FU), in the blood of cancer patients, in Spain and Protugal. INyDIA will provide My5-FU test kits to ...
Tags: medical research, medical test, clinical research, company collaboration
Saladax Biomedical has signed a diagnostic agreement with Eilaf Pharma for My5-FU diagnostic test in Egypt and throughout the Middle East North African (MENA) region. The test will measure the levels of an anti-cancer drug, ...
Tags: My5-FU diagnostic test, medical research, medical test
Hospira has announced the US re-launch of oxaliplatin injection, a generic version of Sanofi's chemotherapy medication Eloxatin. Hospira will initially offer the solution form of oxaliplatin injection in 50mg and 100mg single-use vials, ...
Tags: oxaliplatin injection, Sanofi's chemotherapy medication, oncology drug
The US Patent and Trademark Office (USPTO) has granted three new patents to A.P. Pharma's new APF530 drug delivery candidate. The company said APF530 drug candidate is being developed for the prevention of both acute- and delayed-onset ...
Tags: US Patent, A.P.Pharma, APF530 drug delivery candidate, New Drug Delivery
Sagent Pharmaceuticals,a specialty pharmaceutical company,has launched Ondansetron Injection,USP,an antiemetic,in two latex-free vial presentations. Ondansetron Injection,USP is indicated for prevention of nausea and vomiting associated ...
Onco Therapies,a wholly owned subsidiary of Strides Arcolab,has received US Food and Drug Administration approval for Cisplatin injection. Cisplatin is a chemotherapy drug used to treat various types of cancers,including ...
Tags: Onco Therapies, Strides Arcolab, Cisplatin injection, chemotherapy drug
Eli Lilly and Company Alimta(pemetrexed for injection)has received FDA approval for new use in the continuation maintenance setting for advanced or metastatic nonsquamous non-small cell lung cancer(NS NSCLC). The approval was based on ...
Cancer Treatment Centers of America(CTCA)at Western Regional Medical Center(WRMC)in Arizona,US,has purchased BSD Medical's BSD-2000 Hyperthermia system. CTCA,which is comprised of a network of hospitals including WRMC,provides effective ...
Tags: CTCA, BSD 2000 Hyperthermia system, cancer treatments, WRMC
BSD Medical has featured its hyperthermia product line at International Congress of Hyperthermic Oncology (ICHO), which was held as a joint conference with the Japanese Congress of Thermal Medicine in Kyoto, Japan, in 2012. BSD's ...
Tags: hyperthermia product line, sarcoma, prostate
Carbon design Group has signed Irish Malig as Senior Design Researcher&Strategist."Irish is a terrific addition to our team,"commented Linda Wagner,Carbon's Director of Research&Strategy."She demonstrates a deep curiosity for understanding ...
Results are interesting for treating skin cancer(melanoma)and nervous system tumors,known as gliomas. "Promising results"-Pablo Botella,researcher at the Institute of Chemical Technology of Valencia. Spanish researchers have ...
Janssen Research and Development has received the Priority Review for the supplemental New Drug Application (sNDA) for ZYTIGA from US Food and Drug Administration (FDA). Zytiga (abiraterone acetate) is administered in combination with ...
Tags: sNDA, priority review, FDA
The US Food and Drug Administration (FDA) has approved ZALTRAP (ziv-aflibercept) injection to be used in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) to treat patients with metastatic colorectal cancer (mCRC) that is ...
Tags: Zaltrap Injection, Medicine
Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) have received an approval from US Food and Drug Administration (FDA) to expand the use of Erbitux in combination with the chemotherapy regimen Folfiri as an initial treatment of patients with ...
Tags: FDA approval, Erbitux, KRAS mutation-negative colorectal cancer